2,1,3-苯并噻二唑-4-胺 | 767-63-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 2,1,3-苯并噻二唑-4-胺
• 中文别名: 4-氨基苯并呋扎；2,1,3-苯并恶二唑-4-胺
• 英文名称: 4-aminobenzofurazan
• 英文别名: benzo[c][1,2,5]oxadiazol-4-amine；2,1,3-benzooxadiazol-4-ylamine；2,1,3-Benzoxadiazol-4-amine
• CAS: 767-63-5
• 化学式: C₆H₅N₃O
• mdl: MFCD00168448
• 分子量: 135.125
• InChiKey: IPCMVRZVNJHUHR-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C
• 沸点：
  290.4±32.0 °C(Predicted)
• 密度：
  1.421±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090

SDS

Name:	2 1 3-Benzoxadiazol-4-amine 97% Material Safety Data Sheet
Synonym:	4-Aminobenzofurazan
CAS:	767-63-5

Section 1 - Chemical Product MSDS Name:2 1 3-Benzoxadiazol-4-amine 97% Material Safety Data Sheet
Synonym:4-Aminobenzofurazan

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
767-63-5	2,1,3-Benzoxadiazol-4-amine	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 767-63-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 108 - 110 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H5N3O
Molecular Weight: 135

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 767-63-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,1,3-Benzoxadiazol-4-amine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 767-63-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 767-63-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 767-63-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,1,3-苯并噻二唑-4-胺 在 palladium on activated charcoal 盐酸 、 氢气 、 sodium nitrite 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 2.0h， 生成 2,1,3-苯并噁二唑-4,5-二胺
  参考文献：
  名称：

  Interaction of 4-aminobenzofurazan with aryldiazonium salts

  摘要：

  DOI：

  10.1007/bf01184894
• 作为产物：
  描述：

  4-硝基-2,1,3-苯噁二唑 在 palladium on activated charcoal 、 氢气 作用下， 以 四氢呋喃 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 生成 2,1,3-苯并噻二唑-4-胺
  参考文献：
  名称：

  一种联芳基氨基胍衍生物

  摘要：

  本公开涉及式II所示的联芳基氨基胍衍生物或其药学上可接受的盐及其制备方法。本公开还涉及这种联芳基氨基胍衍生物用于治疗涉及黑素皮质素受体或有关系统例如促黑素细胞激素相关的疾病的用途。

  公开号：

  CN114773314A

文献信息

• Novel 1-Aminomethylisatins: Peculiarities of the Synthesis and the Reaction with Tris(diethylamino)phosphine
  作者：Andrei V. Bogdanov、Lenar I. Musin、Anton V. Il'in、Vladimir F. Mironov

  DOI：10.1002/jhet.2011

  日期：2014.7

  The Mannich reaction of isatin with different primary and secondary amines and effect of the substituent in aromatic amines on the reaction pathway is studied. The efficient high‐yield synthesis of novel isoindigo derivatives by the mild deoxygenation reaction of the corresponding isatins with tris(diethylamino)phosphine is described.

  研究了靛红与不同伯胺和仲胺的曼尼希反应以及芳香胺中取代基对反应路径的影响。描述了通过相应的靛红与三（二乙氨基）膦的温和脱氧反应，高效高效地合成新型异靛蓝衍生物的方法。
• Band gap control in conjugated oligomers and polymers via Lewis acids
  申请人：Bazan Guillermo C.

  公开号：US20110028656A1

  公开（公告）日：2011-02-03

  A method for altering the electronic and optical properties of a chemical compound having a band gap and a framework that includes π-delocalized electrons. The method includes complexing a Lewis acid to a basic site within the framework to form a Lewis acid adduct having a band gap that differs from the band gap of the chemical compound. The λ max of the Lewis acid adduct can be shifted to a longer wavelength in comparison to the λ max of the chemical compound. In various versions, the chemical compound can be a conjugated oligomer, a conjugated polymer, or a small molecule comprising a conjugated π-electron system. Electronic devices that include Lewis acid adducts are also provided.

  一种改变具有带隙和包含π-离域电子的化合物的电子和光学性质的方法。该方法包括将Lewis酸络合到框架内的碱性位点，形成具有与化合物不同带隙的Lewis酸加合物。与化合物的λmax相比，Lewis酸加合物的λmax可以向更长波长移动。在各种版本中，化合物可以是共轭寡聚体、共轭聚合物或包含共轭π-电子系统的小分子。还提供包括Lewis酸加合物的电子器件。
• Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors
  作者：Pei-Tzu Huang、Sirle Saul、Shirit Einav、Christopher R. M. Asquith

  DOI：10.3390/molecules26237338

  日期：——

  Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

  新兴病毒感染，包括那些由登革热病毒（DENV）和委内瑞拉马脑炎病毒（VEEV）引起的感染，构成了全球重大的健康挑战。在这里，我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物，每个化合物占据着不同的化学空间，包括3-((6-溴喹啉-4-基)氨基)酚（12）、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺（50）和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮（52），对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性，CC50值大于10 µM。此外，主导化合物被筛选用于对抗VEEV，并在低个位数微摩尔范围内展示了活性，其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力，以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。
• Triazole derivatives
  申请人：——

  公开号：US20030216385A1

  公开（公告）日：2003-11-20

  The invention relates to a triazole derivative with an activity inhibiting glycine transporter and for use as a pharmaceutical drug, and a novel triazole derivative. The inventive triazole derivative has an excellent activity inhibiting glycine transporter and is useful as a therapeutic agent of dementia, schizophrenia, cognitive disorders, or cognitive disorders involved in various diseases such as Alzheimer disease, Parkinson's disease, or Huntington disease or the like, or spasm involved in diseases such as nerve degenerative diseases and cerebrovascular disorders, or the like. Particularly, the pharmaceutical drug is useful for the amelioration of learning disability of dementia and the like.

  该发明涉及一种三唑衍生物，具有抑制甘氨酸转运体活性，并用作药物，以及一种新颖的三唑衍生物。这种创新的三唑衍生物具有出色的抑制甘氨酸转运体活性，并可用作治疗痴呆症、精神分裂症、认知障碍或涉及各种疾病如阿尔茨海默病、帕金森病、亨廷顿病等的认知障碍，或涉及神经退行性疾病和脑血管疾病等疾病的痉挛。特别是，这种药物对改善痴呆症等学习障碍非常有用。
• An expeditious synthesis of imatinib and analogues utilising flow chemistry methods
  作者：Mark D. Hopkin、Ian R. Baxendale、Steven V. Ley

  DOI：10.1039/c2ob27002a

  日期：——

  A flow-based route to imatinib, the API of Gleevec, was developed and the general procedure then used to generate a number of analogues which were screened for biological activity against Abl1. The flow synthesis required minimal manual intervention and was achieved despite the poor solubility of many of the reaction components.

  一种基于流动的伊马替尼合成路线被开发出来，伊马替尼是药物Gleevec的有效成分。随后，这一通用程序被用来生成众多类似物，并对这些类似物进行了生物活性筛选，目的是对抗Abl1。流动合成过程仅需最少的人工干预，尽管许多反应组分的溶解性较差，但这一目标仍然得以实现。